Rising Biosciences Inc (RBII)

[DezzyDazzler11]

lol RBII calculated PPS projection. Time magazine: 'In 2016, the pharmaceutical companies that make opioid painkillers raked in $8.6 billion in sales for 336 million opioid prescriptions'
now let's calculate what RSII's Share Price will be if we capture just 1/10th of 1% of that 8.6B$ pie, with Cannophen and the FDA candidate pain relief cream. 1/10th of 1% of 8.6B$ = 8.6Million$, divide that by the outstanding share count of 471million rSII shares (according to Bloomberg terminal) you get = EPS (earnings per share) 0.018, which is coincidentally where the share price was earlier this year, just on the strength of Cannophen development in our labs.

so, 8.6Million$ / 471million RBII shares = 0.018 EPS (earnings per share)

EPS x P/E ratio of 25 = Projected Price Per Share = 45 cents


Now, if RSII successfully captures a very modest 1% of that 8.6B$ opioid painkiller market, which will be phased out eventually, and is entirely possibly given RSII has developed Cannophen, and could very well get fast track FDA orphan drug status, considering opioids are causing an epidemic, and awaiting FDA approval on TSW etc. just multiply the final sum from the previous formula by 10 since, 1% would be 10x 1/10th of 1%. and what do we get PPS = 4 dollars & 45 cents.

that is a very lowball estimate considering RSII has the potential to monopolize the burgeoning market of alternative pain-relief medications now that it is known that President Trump has made it his duty to combat the opioid painkiller epidemic. He even ousted Attny General Jeff Sessions last week. That leaves RSII in perfect position to mass produce Cannophen and TSW to combat the opioid epidemic and take its share of the 8.6Billion $ opioid painkiller pie.

The Pain Management Therapeutics Market will surpass the opioid painkiller market 10-fold by the year 2024. So really, if RBII only captures 1/10th of 1% (0.001%) of the Pain Management Therapeautics market, which is projected to be worth 83 Billion dollars come 2024, that would bring RBII's market valuation to somewhere in the neighborhood of 83 Million $. Somewhere in the neighborhood of 1 hundred million dollars.
Hypothetical: RBII captures 1/10th of 1%, (0.001%) of the Pain Management Therapeutic market by the year 2024,
83,000,000$ / 471 million RBII shares = 0.176 EPS (earnings per share)

EPS x P/E ratio of 25 = Projected Price Per Share = 4.40$ RBII 2024.

https://globenewswire.com/news-release/2016/09/28/875315/0/en/Pain-Management-Therapeutics-Market-to-Reach-US-83-0-Billion-by-2024-Transparency-Market-Research.html